Research Studies
Back to Results
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Details
Age
Adult
Type of Study
Treatment
Locations
Memorial Hospital Central
Memorial Hospital North
Pikes Peak Regional Hospital
Principal Investigator
Uchenna Njiaju
Study ID
Protocol Number: 19-6509
More information available at ClinicalTrials.gov: NCT03975647
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers